Myriad Genetics, Inc. (MYGN) Social Stream



Myriad Genetics, Inc. (MYGN): $20.93

0.59 (+2.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MYRIAD GENETICS INC (MYGN) Price Targets From Analysts

Use the tables below to see what analysts covering MYRIAD GENETICS INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-04 6 $35 $26 $30.6 $19.45 57.33%
2022-02-25 6 $33 $26 $29.4 $19.45 51.16%
2022-02-28 6 $32 $24 $28.4 $19.45 46.02%
2022-03-03 6 $30 $24 $27.2 $19.45 39.85%
2022-04-04 6 $30 $24.001 $27.2 $19.45 39.85%
2022-04-20 6 $29 $24.001 $26.8 $19.45 37.79%
2022-05-06 6 $29 $24.001 $26.6 $19.45 36.76%
2022-05-09 6 $27 $22 $25 $19.45 28.53%
2022-06-03 6 $27 $20 $23.2 $19.45 19.28%
2022-07-15 6 $26 $20 $22.8 $19.45 17.22%
2022-08-13 6 $32 $20 $25.6 $19.45 31.62%
2022-09-17 6 $32 $20 $26.4 $19.45 35.73%
2022-10-06 7 $32 $20 $25.666 $19.45 31.96%
2022-10-17 6 $32 $20 $25.666 $19.45 31.96%
2022-11-01 6 $32 $20 $25.166 $19.45 29.39%
2022-11-02 7 $27 $20 $23.833 $19.45 22.53%
2022-11-03 7 $25 $18 $21.166 $19.45 8.82%

The Trend in the Analyst Price Target


MYGN's average price target has moved down $6.03 over the prior 30 weeks.

MYGN reports an average of 18.77% for its upside potential over the past 43 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-02-25 6 33 26 29.400 24.69 19.08%
2022-03-03 6 30 26 28.000 23.48 19.25%
2022-09-17 6 32 20 26.400 21.37 23.54%
2022-10-06 7 32 20 25.666 20.41 25.75%
2022-10-17 6 32 20 25.666 19.66 30.55%

MYGN Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
3.43 0 0 5 1 1 7

The Trend in the Broker Recommendations


Over the past 52 weeks, MYGN's average broker recommendation rating improved by 0.07.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MYGN as an investment opportunity.

  • MYRIAD GENETICS INC's variance in analysts' estimates is lower than -532.45% of all US stocks.
  • In terms of how MYRIAD GENETICS INC fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is higher than 365.27% of that group.
  • In the context of stocks in the mid market cap category, MYRIAD GENETICS INC's average analyst price target is greater than 657.5% of them.
  • In terms of how MYRIAD GENETICS INC fares relative to stocks in the mid market cap category, note that its number of analysts covering the stock is greater than 722.83% of that group.

Stocks similar to MYRIAD GENETICS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CLDX, NEOG, and EVO.

Is MYGN a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6164 seconds.